Vanguard Group Inc Celldex Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,739,039 shares of CLDX stock, worth $124 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,739,039
Previous 3,650,582
2.42%
Holding current value
$124 Million
Previous $153 Million
9.68%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CLDX
# of Institutions
195Shares Held
63.4MCall Options Held
206KPut Options Held
176K-
Wellington Management Group LLP Boston, MA8.08MShares$268 Million0.05% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$156 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.39MShares$113 Million9.76% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$110 Million2.17% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.17MShares$105 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.55B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...